Synthesis and biological evaluation of second-generation tropanol-based androgen receptor modulators

Journal of Medicinal Chemistry

Volumn 58, Issue 3, 2015, Pages 1569-1574

  Sundén, Henrik ^a   Holland, Mareike C ^a   Poutiainen, Pekka K ^c,d   Jääskeläinen, Tiina ^c   Pulkkinen, Juha T ^c   Palvimo, Jorma J ^c,e   Olsson, Roger ^a,b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

SELECTIVE ANDROGEN RECEPTOR MODULATOR; TROPINE; ANDROGEN RECEPTOR; ANDROGEN RECEPTOR ANTAGONIST; LIGAND; TROPANE DERIVATIVE;

ANIMAL CELL; ARTICLE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DRUG SYNTHESIS; EVALUATION STUDY; IC50; LIGAND BINDING; NONHUMAN; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION; WILD TYPE; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; GENETICS; HUMAN; METABOLISM; MUTATION; SYNTHESIS;

ANDROGEN RECEPTOR ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LIGANDS; MOLECULAR STRUCTURE; MUTATION; RECEPTORS, ANDROGEN; STRUCTURE-ACTIVITY RELATIONSHIP; TROPANES;

EID: 84922824050     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm501995n     Document Type: Article

References (42)

1. Salvati, M. E.; Balog, A.; Wei, D. D.; Pickering, D.; Attar, R. M.; Geng, J.; Rizzo, C. A.; Hunt, J. T.; Gottardis, M. M.; Weinmann, R.; Martinez, R. Identification of a novel class of androgen receptor antagonists based on the bicyclic-1 H -isoindole-1,3(2 H)-dione nucleus Bioorg. Med. Chem. Lett. 2005, 15, 389-393
2. Zhang, X.; Li, X.; Allan, G. F.; Sbriscia, T.; Linton, O.; Lundeen, S. G.; Sui, Z. Design, synthesis, and in vivo SAR of a novel series of pyrazolines as potent selective androgen receptor modulators J. Med. Chem. 2007, 50, 3857-3869
3. Zhao, S.; Shen, Y.; van Oeveren, A.; Marschke, K. B.; Zhi, L. Discovery of a novel series of nonsteroidal androgen receptor modulators: 5- or 6-oxachrysen-2-ones Bioorg. Med. Chem. Lett. 2008, 18, 3431-3435
4. Salvati, M. E.; Balog, A.; Shan, W.; Rampulla, R.; Giese, S.; Mitt, T.; Furch, J. A.; Vite, G. D.; Attar, R. M.; Jure-Kunkel, M.; Geng, J.; Rizzo, C. A.; Gottardis, M. M.; Krystek, S. R.; Gougoutas, J.; Galella, M. A.; Obermeier, M.; Fura, A.; Chandrasena, G. Identification and optimization of a novel series of [2.2.1]-oxabicyclo imide-based androgen receptor antagonists Bioorg. Med. Chem. Lett. 2008, 18, 1910-1915
5. Attar, R. M.; Jure-Kunkel, M.; Balog, A.; Cvijic, M. E.; Dell-John, J.; Rizzo, C. A.; Schweizer, L.; Spires, T. E.; Platero, J. S.; Obermeier, M.; Shan, W.; Salvati, M. E.; Foster, W. R.; Dinchuk, J.; Chen, S.-J.; Vite, G.; Kramer, R.; Gottardis, M. M. Discovery of BMS-641988, a novel and potent inhibitor of androgen receptor signaling for the treatment of prostate cancer Cancer Res. 2009, 69, 6522-6530
6. Poutiainen, P. K.; Oravilahti, T.; Peräkylä, M.; Palvimo, J. J.; Ihalainen, J. A.; Laatikainen, R.; Pulkkinen, J. T. Design, synthesis, and biological evaluation of nonsteroidal cycloalkane[ d ]isoxazole-containing androgen receptor modulators J. Med. Chem. 2012, 55, 6316-6327
7. Guo, C.; Pairish, M.; Linton, A.; Kephart, S.; Ornelas, M.; Nagata, A.; Burke, B.; Dong, L.; Engebretsen, J.; Fanjul, A. N. Design of oxobenzimidazoles and oxindoles as novel androgen receptor antagonists Bioorg. Med. Chem. Lett. 2012, 22, 2572-2578
8. Yamamoto, S.; Kobayashi, H.; Kaku, T.; Aikawa, K.; Hara, T.; Yamaoka, M.; Kanzaki, N.; Hasuoka, A.; Baba, A.; Ito, M. Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists Bioorg. Med. Chem. 2013, 21, 70-83
9. Gao, W.; Bohl, C. E.; Dalton, J. T. Chemistry and structural biology of androgen receptor Chem. Rev. 2005, 105, 3352-3370
10. Taplin, M.-E. Drug Insight: role of the androgen receptor in the development and progression of prostate cancer Nature Clin. Pract. Oncol. 2007, 4, 236-244
11. Chen, Y.; Clegg, N. J.; Scher, H. I. Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target Lancet Oncol. 2009, 10, 981-991
12. Haendler, B.; Cleve, A. Recent developments in antiandrogens and selective androgen receptor modulators Mol. Cell. Endocrinol. 2012, 352, 79-91
13. Feldman, B. J.; Feldman, D. The development of androgen-independent prostate cancer Nature Rev. Cancer 2001, 1, 34-45
14. Chen, Y.; Sawyers, C. L.; Scher, H. I. Targeting the androgen receptor pathway in prostate cancer Curr. Opin. Pharmacol. 2008, 8, 440-448
15. Donkena, K. V.; Yuan, H.; Young, C. Y. Recent advances in understanding hormonal therapy resistant prostate cancer Curr. Cancer Drug Targets 2010, 10, 402-410
16. Knudsen, K. E.; Penning, T. M. Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer Trends Endocrinol. Metab. 2010, 21, 315-324
17. Miyamoto, H.; Rahman, M. M.; Chang, C. Molecular basis for the antiandrogen withdrawal syndrome J. Cell. Biochem. 2003, 91, 3-12
18. Bergerat, J.-P.; Ceraline, J. Pleiotropic functional properties of androgen receptor mutants in prostate cancer Hum. Mutat. 2009, 30, 145-157
19. Brooke, G. N.; Bevan, C. L. The role of androgen receptor mutations in prostate cancer progression Curr. Genomics 2009, 10, 18-25
20. Koochekpour, S. Androgen receptor signaling and mutations in prostate cancer Asian J. Androl. 2010, 12, 639-657
21. McGinley, P. L.; Koh, J. T. Circumventing anti-androgen resistance by molecular design J. Am. Chem. Soc. 2007, 129, 3822-3823
22. Zhou, J.; Geng, G.; Shi, Q.; Sauriol, F.; Wu, J. H. Design and synthesis of androgen receptor antagonists with bulky side chains for overcoming antiandrogen resistance J. Med. Chem. 2009, 52, 5546-5550
23. Duke, C. B.; Jones, A.; Bohl, C. E.; Dalton, J. T.; Miller, D. D. Unexpected binding orientation of bulky-B-ring anti-androgens and implications for future drug targets J. Med. Chem. 2011, 54, 3973-3976
24. Lipinski, C. A. Lead- and drug-like compounds: the rule-of-five revolution Drug Discovery Today: Technol. 2004, 1, 337-341
25. Tran, C.; Ouk, S.; Clegg, N. J.; Chen, Y.; Watson, P. A.; Arora, V.; Wongvipat, J.; Smith-Jones, P. M.; Yoo, D.; Kwon, A.; Wasielewska, T.; Welsbie, D.; Chen, C. D.; Higano, C. S.; Beer, T. M.; Hung, D. T.; Scher, H. I.; Jung, M. E.; Sawyers, C. L. Development of a second-generation antiandrogen for treatment of advanced prostate cancer Science 2009, 324, 787-790
26. Jung, M. E.; Ouk, S.; Yoo, D.; Sawyers, C. L.; Chen, C.; Tran, C.; Wongvipat, J. Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC) J. Med. Chem. 2010, 53, 2779-2796
27. Scher, H. I.; Beer, T. M.; Higano, C. S.; Anand, A.; Taplin, M.-E.; Efstathiou, E.; Rathkopf, D.; Shelkey, J.; Yu, E. Y.; Alumkal, J.; Hung, D.; Hirmand, M.; Seely, L.; Morris, M. J.; Danila, D. C.; Humm, J.; Larson, S.; Fleisher, M.; Sawyers, C. L. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 375, 1437-1446.
28. Lund, B. W.; Piu, F.; Gauthier, N. K.; Eeg, A.; Currier, E.; Sherbukhin, V.; Brann, M. R.; Hacksell, U.; Olsson, R. Discovery of a potent, orally available, and isoform-selective retinoic acid beta 2 receptor agonist J. Med. Chem. 2005, 48, 7517-7519
29. Piu, F.; Gauthier, N. K.; Olsson, R.; Currier, E. A.; Lund, B. W.; Croston, G. E.; Hacksell, U.; Brann, M. R. Identification of novel subtype selective RAR agonists Biochem. Pharmacol. 2005, 71, 156-162
30. Piu, F.; Cheevers, C.; Hyldtoft, L.; Gardell, L. R.; Del Tredici, A. L.; Andersen, C. B.; Fairbairn, L. C.; Lund, B. W.; Gustafsson, M.; Schiffer, H. H.; Donello, J. E.; Olsson, R.; Gil, D. W.; Brann, M. R. Broad modulation of neuropathic pain states by a selective estrogen receptor beta agonist Eur. J. Pharmacol. 2008, 590, 423-429
31. Piu, F.; Gardell, L. R.; Son, T.; Schlienger, N.; Lund, B. W.; Schiffer, H. H.; Vanover, K. E.; Davis, R. E.; Olsson, R.; Bradley, S. R. Pharmacological characterization of AC-262536, a novel selective androgen receptor modulator J. Steroid Biochem. Mol. Biol. 2008, 109, 129-137
32. Lund, B. W.; Knapp, A. E.; Piu, F.; Gauthier, N. K.; Begtrup, M.; Hacksell, U.; Olsson, R. Design, synthesis, and structure-activity analysis of isoform-selective retinoic acid receptor beta ligands J. Med. Chem. 2009, 52, 1540-1545
33. Sunden, H.; Olsson, R. Asymmetric synthesis of a tricyclic benzofuran motif: a privileged core structure in biologically active molecules Org. Biomol. Chem. 2010, 8, 4831-4833
34. Sauvee, C.; Schäfer, A.; Sunden, H.; Ma, J.-N.; Gustavsson, A.-L.; Burstein, E. S.; Olsson, R. The A-CD analogue of 16β,17α-estriol is a potent and highly selective estrogen receptor β agonist MedChemComm 2013, 4, 1439-1442
35. Sundén, H.; Ma, J.-N.; Hansen, L. K.; Gustavsson, A.-L.; Burstein, E. S.; Olsson, R. Design of a highly selective and potent class of nonplanar estrogen receptor β agonists ChemMedChem 2013, 8, 1283-1294
36. Acevedo, S.; Gardell, L.; Bradley, S. R.; Piu, F.; Raber, J. Selective androgen receptor modulators antagonize apolipoprotein E4-induced cognitive impairments Lett. Drug Des. Discovery 2008, 5, 271-276
37. Schlienger, N.; Lund, B. W.; Pawlas, J.; Badalassi, F.; Bertozzi, F.; Lewinsky, R.; Fejzic, A.; Thygesen, M. B.; Tabatabaei, A.; Bradley, S. R.; Gardell, L. R.; Piu, F.; Olsson, R. Synthesis, structure-activity relationships, and characterization of novel nonsteroidal and selective androgen receptor modulators J. Med. Chem. 2009, 52, 7186-7191
38. George, S.; Petit, G. H.; Gouras, G. K.; Brundin, P.; Olsson, R. Nonsteroidal selective androgen receptor modulators and selective estrogen receptor β agonists moderate cognitive deficits and amyloid-β levels in a mouse model of alzheimer's disease ACS Chem. Neurosci. 2013, 4, 1537-1548
39. Thompson, J.; Saatcioglu, F.; Jänne, O. A.; Palvimo, J. J. Disrupted amino- and carboxyl-terminal interactions of the androgen receptor are linked to androgen insensitivity Mol. Endocrinol. 2001, 15, 923-935
40. Bergerat, J.-P.; Ceraline, J. Pleiotropic functional properties of androgen receptor mutants in prostate cancer Hum. Mutat. 2009, 30, 145-157
41. Brooke, G. N.; Bevan, C. L. The role of androgen receptor mutations in prostate cancer progression Curr. Genomics 2009, 10, 18-25
42. Koochekpour, S. Androgen receptor signaling and mutations in prostate cancer Asian J. Androl. 2010, 12, 639-657